You are on page 1of 2

Verano 2012

)*(+,#-'&.#/7/2862*"/
José Joaquín Serrano

Alumno de la Licenciatura en Biología de la Universidad de Málaga
conguino@hotmail.com

!"#$%&'(#

!"# $%&'$%()*"# +%# ,-*%')."(,/-#%-#%0# (1-(%&# 2"# %'3"+4# 5"'"+"#+6&"-3%# 76(24#)%7$4# %-# 0"# +%3%((,/-# +%# "86%004'#.%-%' #
,7$0,("+4'#%-#0"#3&"-'94&7"(,/-#3674&,.:-,(";#<'#(,%&34#86%#%0#$%'4#+%#:'34'#%-#0"#"$"&,(,/-#+%# 0"' #(:060"'#("-(%&4'"'#%'31# 71'#
86%# (4-3&"'3"+4#=!"-%>#?@@AB>#$%&4#%-#04'#C0)74'#)%7$4'#'%# 2"-#2%(24#-67%&4'4'#"*"-(%'#%-#0"# (47$&%-',/-#+%# (/74#%0#
7%3"540,'74#+%# 0"' #(:060"'#("-(%&4'"'#0%'#$%&7,3%#7"-3%-%&#6-#9%-4)$4#7"0,.-4># 2"'3"#%0#$6-34#+%#00%."&#"# '%&#+%',.-"+4#&%D
(,%-3%7%-3%#(474#6-"#+%#0"'#-6%*"'#'%E"'#+%#,+%-)+"+#+%0#(1-(%&# =F"-"2"-#G#H%,-5%&.>#AI??B;#J4#%'3"74'#"-3%#"0.4#-6%*4#
(6"-+4#&%0"(,4-"74'#%0#7%3"540,'74#(4-#%0#(1-(%&K# %0#$,4-%&4#%-#"3&,56,&#"0#7%3"540,'74#6-#$"$%0#,7$4&3"-3%#%-#%0#$&4(%'4#
3674&"0#96%#%0#$&%7,4#J45%0#LM4#H"&56.>#86,%-#"001#$4&#04' #"E4'#AI#+%0#',.04#$"'"+4#45'%&*/#86%#0"'#(:060"'#3674&"0%' #$&%'%-D
3"5"-#6-"' #%0%*"+"'#3"'"' #+%#6)0,N"(,/-#+%# .06(4'"# +%# 7"-%&"# ,-+%$%-+,%-3%# "0#7%3"540,'74#4O,+")*4>#"#$%'"&#+%# 2"00"&'%#"#
6-"'#3%-',4-%'#+%#4OP.%-4#%0%*"+"'#=H"&56.>#?@AQB;# <0#"+*%-,7,%-34#+%# 0"' #-6%*"'#2%&&"7,%-3"'#+%#0"# 5,404.P"#740%(60"&#&%0%D
./#"#0"#5,486P7,("#(01',("#"# 6-#'%.6-+4#$0"-4>#G#0"#,-*%')."(,/-#51',("#%-#7%3"540,'74#86%+/#"0.4#%'3"-("+";#R%&4#2"# &%'6&.,D
+4#(4-#96%&N"#%-#04' #C0)74' #"E4' #%0# ,-3%&:'#$4&#%0#7%3"540,'74#3674&"0>#'45&%#34+4#.&"(,"'#"#"6-"&#96%&N"'#%-3&%# 0"'#-6%*"'#
3%(-404.P"'#G#0"'#7%34+404.P"'#51',("';#S,# 45T%)*4#%-#0"#$&%'%-3%# &%*,',/-# %'# $&%'%-3"&# "0.6-4'#+%# 04'#+%'(65&,7,%-34' #71'#
,7$4&3"-3%'#%-#%0#175,34#+%0#7%3"540,'74#%-#0"'#(:060"'#("-(%&4'"';

35

)*(+,#-'&.#/0-1234'2#/(1.#"+-

R4&#,7$4&3"-(,"#2,'3/&,(">#2"5&P"# 86%# (47%-N"&#2"50"-+4#+%#0"#$"&3%#71'#("&"(3%&P')("# ="#$&,4&,B#+%0#7%3"540,'74#3674&"0>#
%0# %9%(34#H"&56.;# U86P>#04'#"*"-(%'#71'#',.-,V(")*4'#*,%-%-#+%# 0"# %06(,+"(,/-#+%# 0"# ,+%-)+"+#+%# 04'#3&"-'$4&3"+4&%'#,7$0,("D
+4'#%-#0"#("$3"(,/-#+%#.06(4'"#G>#'45&%#34+4>#+%0#$"$%0#+%0#0"(3"34#%-#%0#(1-(%&>#"(36"-+4#(474#6-"#$4',50%# 740:(60"#'%E"0#86%#
$6%+"#+%'%-("+%-"&#$&4(%'4'#96-+"7%-3"0%'#(474#0"# "-.,4.:-%','>#0"#,-*"',*,+"+#3674&"0# =9"*4&%(,+"# $4&# %0#"75,%-3%# 1(,+4#
.%-%&"+4#$4&#%0#$&4$,4#0"(3"34B#4#0"#$&4$,"#&%.60"(,/-#+%0#7%3"540,'74#3674&"0#=F'6#G#W"5")-,>#AIIXB;
Y%-3&4#+%#0"#$&4$,"#&63"# .06(40P)("#$4+%74'#%-(4-3&"&#43&"'#$"&3%'#+%#0"# 7,'7"#"03%&"+";#<'#,-3%&%'"-3%#0"# %O,'3%-(,"#%-#0"#
(:060"#3674&"0#+%#6-"#,'4%-N,7"#+%#0"#$,&6*"34#(,-"'"#=RZB>#0"#RZDSA;#<'3"#,'494&7"#%' #7%-4'#"()*"#86%#0"#RZ#G#'6#%O$&%',/->#%-#
+%3&,7%-34#+%#0"#,'494&7"#[-4&7"0[>#$%&7,3%#86%# 04'#94'947%3"540,34' #"-3%&,4&%'#"0#94'94%-40$,&6*"34#=R<RB>#$6%+"-#"(6760"&D
'%#G#'%&#6)0,N"+4'#%-#0"#'P-3%','#+%#(47$6%'34'#-%(%'"&,4'#$"&"#7"-3%-%&#0"#$&40,9%&"(,/-#(%060"&>#(474#'4-#"7,-41(,+4'>#1(,+4'#
-6(0%,(4'#G#0P$,+4'#=S"N6&%\#!"#$%>#AII]>#Z&4%7%&#G#R46G''%.6&>#AIIXB;
!0%."+4'#"# %'3%# $6-34#%'#24&"#+%# 2"(%&# 7%-(,/-#"# 6-"#740:(60"# 86%#"+86,%&%#("+"#*%N#71'#,7$4&3"-(,"# %-#$&4(%'4'#&%0"D
(,4-"+4'#(4-#%0#(1-(%&;#<'3"#740:(60"#-4#%'#43&"#86%#%0#9"(34&#+%#3&"-'(&,$(,/-#F^_D?#=+%0#,-.0:'#&'()*+$#+,-./+0%!#1$/")234B;#F^_D
?#%'#6-#2%3%&4+P7%&4#(47$6%'34#$4&#6-"#'656-,+"+#5%3"#86%# '%# %O$&%'"# (4-')36)*"7%-3%# G#6-"#'656-,+"+#"09"#86%# '%#',-3%D
)N"#G#'%#+%.&"+"# %-#(4-+,(,4-%'#-4&7/O,("';# <'#%'3"#'656-,+"+#"09"#0"#86%# "+86,%&%#6-#$"$%0#&%0%*"-3%# %-#%0#(1-(%&;# U6-86%#
F^_D?#%'#96-+"7%-3"0#%-#%0#$&4(%'4#+%# 0"#"-.,4.:-%','>#(6"-+4#%0#3674&#'%#%-(6%-3&"#5"T4#(4-+,(,4-%'#+%#2,$4O,"#0"#&%.60"(,/-#
+%#'6#'P-3%','#G# %0,7,-"(,/-#$"&%(%#$&4*4("&# 3"75,:-#("75,4'#7%3"5/0,(4' #+%# ,7$4&3"-(,"# $"&"#0"#(:060"#3674&"0;# R"&"# '6#+%D
.&"+"(,/->#F^_D?#%'#7"&("+4#'%(6%-(,"07%-3%# $4&#0"#%-N,7"# $&40,0#2,+&4O,0"'"#G#6-"#65,86,)-"#0,."'"#=`F!>#9"(34&#+%#`4-#F,$$%0#
!,-+"6B#$"&"#'6#$4'3%&,4&#$&4(%'"7,%-34#$4&#%0#$&43%"'47"#AaW;#W,-#%75"&.4>#763"(,4-%'#%-#0"#0P-%"#.%&7,-"0#+%#+%3%&7,-"+"'#
%-N,7"'#+%0#(,(04#+%# 04'#1(,+4'#3&,("&54OP0,(4'#=bcUB># %-#(4-(&%34#0"'#%-N,7"'#'6((,-"34# +%'2,+&4.%-"'"# G#967"&"34#2,+&"3"'">#
*"-#"# $&474*%&#0"# "(6760"(,/-#+%#04'#7%3"540,34'#'6((,-"34#4#967"&"34>#04'#(6"0%'#,-2,5%-#(47$%))*"7%-3%# #0"#$&40,0#2,+&4O,D
0"'"# %-("&."+"#+%# &%.60"&#0"#+%.&"+"(,/-#+%# F^_D?"09"># 04#86%# $%&7,3%# 86%# %'3"# 740:(60"# $6%+"# +,7%&,N"&#(4-#F^_D?5%3"# =d4D
M0,%5#G#b470,-'4-># AII]B;# !"#("&3"# +%#0,5%&3"+# #$"&"# 0"# "(36"(,/-#+%# F^_D?#*"# "# $%&7,)&#86%#%'3%# 9"(34&#+%# 3&"-'(&,$(,/-#3&"-'D
"()*%# "#0"# $,&6*"34#+%'2,+&4.%-"'"# \,-"'"# ?>#6-"# %-N,7"# 86%# 94'94&,0"# "# 0"#$,&6*"34#+%'2,+&4.%-"'"#G#0"# ,-"()*"># ,7$,+,%-+4#
86%# '%#.%-%&%#"(%)0Dc4U>#+%#94&7"# 86%# :'3%# -4#$6%+%# %-3&"&#%-#%0#bcU#G#.%-%&"&#%86,*"0%-3%' #&%+6(34&%'>#(47$&47%)%-+4#0"#
94'94&,0"(,/-#4O,+")*"#=Z&4%7%&#"-+#R46G''%.6&>#AIIXB;

)*(+,#-'&.#/-'$34'2#/(1.#"+-

<-#0"'#(:060"' #3674&"0%'#3"75,:-#'%#%-(6%-3&"-#'45&%%O$&%'"+"'#%-N,7"'#(0"*%# +%0#7%3"540,'74#0,$P+,(4>#(474#%'#0"# 1(,+4#
.&"'4#',-3"'"# =_UWB;# !"# '45&%%O$&%',/-#+%# %'3"# %-N,7"# $%&7,3%# 7"-3%-%&# 6-"#%0%*"+"# *%04(,+"+#+%# 'P-3%','#+%# 1(,+4'#.&"'4'>#
%'%-(,"0%'# $"&"# 0"# 94&7"(,/-# +%# 7%75&"-"'# $0"'71)("'># '6'3%-3"-+4#+%# %'3"# 94&7"# 0"# $&40,9%&"(,/-# 3674&"0# =H"-.# !"# $%>#
AII]B;#<'3"#'P-3%','#+%# 1(,+4'#.&"'4' #%'#3"75,:-#+%$%-+,%-3%#+%# 0"# +,'$4-,5,0,+"+#+%# $4+%&#&%+6(34&#%-#94&7"#+%# JUYRF>#(6G4#
4&,.%-#'%#2"00"#%-#0"#9"'%#4O,+")*"#+%#0"#&63"#+%#0"'#$%-34'"'#94'9"34#=RRRB>#%'3"50%(,:-+4'%#6-"#&%0"(,/-#%-3&%# 0"#RZDSA#G#0"#_UW#
%-#%0# 7%3"540,'74#3674&"0#=Z&4%7%&# G#R46G''%.6&# AIIX># S%-%-+%N#G#!6$6#AIIeB;# <'3"# .%-%&"(,/-#+%# JUYRF#3"75,:-#'%#*%#
9"*4&%(,+"# $4&# 0"# ,-2,5,(,/-#+%# 0"# %O$&%',/-#+%# 6-#74+60"+4&#+%0#7%3"540,'74#86%# '%# %-(6%-3&"# &%.60"+4#$4&#%0#$&4+6(34#+%0#
.%-#bR]f;#<'3%#74+60"+4&#%'#b^dUg#=+%0#,-.0:'>#56783+,-./!-#9%'/)%':+:#$,-#$()("):+:#2!9.%$")2B>#86%#%-#(4-+,(,4-%'#-4&7"0%'#
"G6+"#"# 7"-3%-%&#04'#-,*%0%'#+%# &"+,("0%'#0,5&%'#+%#4OP.%-4#=gLWB#5"T4'#G#"#"67%-3"&#04'#-,*%0%'#+%#JUYRF>#&%+6(,%-+4#%0#h6T4#
.06(40P)(4;#<-#%0#(1-(%&#0"# %O$&%',/-#+%#b^dUg#%'31#,-2,5,+";#<'34#$6+,%&"#$"&%(%&#(4-3&"D,-36,)*4#%-#6-#$&,7%&#747%-34>#$%&4#
+6&"-3%#%0#$&4(%'4#3674&"0#'%#$&4+6(%# 6-#"67%-34#+%# 0"#.06(40,','>#$4&#04#86%#'6#,-2,5,(,/-#%'#96-+"7%-3"0;#U+%71'>#0"#%O$&%D
',/-#+%#RZDSA#"G6+"#"#86%#+,(24#"67%-34#+%#0"#.06(40,','#$%&7,3"#86%#'%# +%&,*%-#$"&3%#+%#04'#7%3"540,34'#"#0"#&63"#+%# 0"' #$%-D
34'"'#94'9"34#=RRRB#G#"'P#.%-%&"&#JUYRF#%-#.&"-+%'#("-)+"+%'#(4-#%0#45T%34#+%#7"-3%-%&#0"#$&40,9%&"(,/-#(%060"&# =i46-.#G#U-D
+%&'4-#AIIXB;

5162'%6/.'(#2#64"'+-/7/2862*"

!"# 7,34(4-+&,"># (474# .%-%&"+4&# 96-+"7%-3"0# +%# %-%&.P"# (%060"&># 3"75,:-#)%-%# 6-# $"$%0# (&P)(4#%-# %0#$&4.&%'4#2"(,"# %0#
("75,4#7%3"5/0,(4>#'45&%# 34+4#+%5,+4#"# 0"# .%-%&"(,/-#+%# gLW# (474#(4-'%(6%-(,"# +%# 6-#%0%*"+4#7%3"540,'74#4O,+")*4#86%#
%O(%+%# 0"# ("$"(,+"+#+%# 0"# ("+%-"# +%#3&"-'$4&3%# %0%(3&/-,(4#7,34(4-+&,"0#=<bcB;#!"# (%&("-P"#%-3&%#0"#<bc#G#%0#YJU#7,34(4-+&,"0#
2"(%#86%#0"#$&4+6((,/-#+%# gLW>#86%#'4-#".%-3%'#3/O,(4'#$"&"#%0#YJU>#$6%+"#$&4*4("&#763"(,4-%'>#86%#3&6-86%-#0"#<bc#G#.%-%D

Vol.5 ¦ Nº 138-139

Haigis MC.#W%#$.># %-#'6#%-'"G4# +%# AIIX#%-#A!%%>#$0"-3%"-#6-"# '%&.06(4'"# 86%# %'#("$3"+"#+%#-6%*4#$4&# %0# 3674&>#$%&7.#<'%# '%&P"#%0#("'4#+%#0"#%-N./-#%-3&%#7%3"540."#G# %0# (&%(. Poulikakos PI. Kroemer G. Tisdale MJ (2002). Oncogene 24: 3574-3582. Sinclair DA (2010).36"+"# <-)?.-*"'.%-%&"&#$. Di Cristofano A.%-%&"-# 6-"# .94'9"34#("&"(3%&P')(4'#+%0#YJU#=F'6#G#W"5")-. 5-19#&/.%-:)("# 3674&"0%'.%# +%# (6%')4-%'#"(%&("#+%0#7%3"540.*%0#(%060"&>#%-3&%#0"'#(:060"' #3674&"0%'#G#0"'#(:060"'#%'3&471)("'># 6)0.V("(. Tuveson DA.# <'#6-# ("7$4#86%# -%(%'. Cachexia in cancer patients.0"(.'# 7%+.7"#JjY^k>#6-"# 2.%-:)(4>#+4-+%#$4+%74'#%-(4-3&"&#("75.(4'#$"&"#'P#7. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor associated stroma. Posener K.&# AI?IB./-#%'31#$&474*. Bauer DE./-#$4'. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarían carcinoma cells./-.+4'#3&.4# 2"(."(. Cancer cell 13: 472-482 Lane D (1992)./-# +%# 43&"'# +4'# %-N. Hsu P.&"(.(0"+4#+%0#0"(3"34#.(0"+4#'6$4-%>#-4#45'3"-3%>#6-#%0%*"+4#(4'3%# %-%&D .-"'"# =FZB#G#+%#6-#("-"0#"-.(4#+%$%-D +. Skele KL. Tumor cell metabolism: Cancer´s achilles heel./-#+%# +%'"(%)0"'"'#+%$%-+. 319-344.*&(#<'='2+2'%6 b"75. Cancer cell 8: 311-321."+"#$4&#0"#"'4(.+"# $4&#%0#%O(%'4#+%#"(%)0Dc4U#86%#'%#. Tomlinson IP (2005).7.'74># 6-"# '.0.+"# %-#86%# $6%+%-#%'3"50%(%&#h6T4'#(4-#43&"'#$"&3%'#+%0# (6%&$4#+%0# 24'$%+"+4&>#3"-34#"#-.# F'6#G#W"5")-.&36. Young CD.-"'#=F".("#+%'4&5.+&40"'"#86%#"(3C"#'45&%# %0#$440#+%#-6(0%/)+4'#%0.-"()*"(.:"2!$=>># 0"# 7bLg#=Z&4%7%&# G#R4G''%.+"#$4&#U\3>#6-"#\./-#+%#%'3%#)$4#+%#%-N.*%0#+%# 0"#7%75&"-"# 7.."# 0"# .-2. Cancer cell metabolism: Warbug and Beyond.&6*"34>#86%#*6%0*%#"#0"#(:060"' #("-(%&4'"#$"&"#'%&#6)0.%-34# +%0#3674&#=F"3N. Lupu R (2007).7"'#%-#%0#+%'"&&4004#3674&"0.("#$"&"# 86%# 0"# (:060"# 3674&"0# $&4. Eigenbrodt E (2005). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery 8: 579-591. Pouyssegur J (2008).-"+4' #&%'.+%-)+"+#+%0#(1-(%&K#%'3%#%'#%0#("'4#+%# 0"#%*"'. p53.#/(1.#-'&.06(.3"# 71' #3&"5"T4># $%&4#'%# 2"# +%74'3&"+4#86%#0"#'6$&%'.4-"+4'#(4-#%0#7%3"540.&#+%# 7%("-. Biochemie Zentrum 152.("(.:-#$4+%74'#%-(4-3&"&#86%#(474#(4-'%(6%-(. Hingorani SR. Cancer research 66: 632-637.%-'"#86%#0"'#(:060"'#3674&"0%'#$4+&P"-#&%86%&./-#7%3"5/0./-#+%#gLW#$4&#0"#<bc.5%# %0#(&%(.# U\3# $6%+%# &%'603"&# "()*"+"# (474#(4-'%(6%-(.6-3"'#'4-#%0#-6%*4#$6-34#+%# $"&)+"#%-#0"# 06(2"#$4&#(47$&%-+%&#%0#7%3"540. >/-+/*&$*"+/4*/6#?*4+4*& <'3"#%'#'404#6-"#$%86%E"# 76%'3&"#+%#0"#760)36+#+%#$&4(%'4'#&%0"(. Sabatini D (2008). Wang HQ.>#AIIXB.7.+64'#+%#0. Alexandre J./->#0"#(6"0# $"&%(%# %'3"&#$&474*.'74#3674&"0. Dhanak D./-#"#-./-#+%#Rb<J#+%#94&7"#.+%-3%# 0"# &%0"(.7./-#G# 0"# 7%31'3"'. 36 .# <0#7%3"540.N"+4#%-#0"#'P-3%'.")*4#+%# U\3./-#+%#0"#"$4$34'. Seminars cancer biology 15: 300-308.%-34# (%060"&>#"# 3&"*:'#+%# '6# .%&3%# %-#. Testa JR (2005).'74#G#.4'#34+4'#04'#%'3"+4'#+%#"+"$3"(.*%-(. Breast Cancer Research 10: 202-211. Thompson CB (2005).%-%&"+4#%-#%O(%'4#$4&# 0"# (:060"# 3674&"0K# %'3%# &%(."+4>#86%#04#(4-*. Anderson SM (2008). Vol.&%'%# +%'+%# 0"# %3"$"# +%# 3674&#$&.'74#3674&"0># (474#(61-#7"0%"50%#%'#%0#7%3"540.+"&#0"#. Shaw AN..)*"# 86%#$6%+%# 9"*4&%(%&#%0#$&4D (%'4#3674&"0#=b&"(244327"-#!"#$%.%#+%#(.'#4#'.5.&.-3%&"((.60"+4&#-%."0#%O3%&-"#+%# 0"# 2%O486. Cell 134: 703-708 Koukourakis MI.#!"# . the guardian of genome.:-#74+.V("#43&"'#'%E"'#+%# .-2.3&"34#0.#%-3&%# %0#24'$%+"+4&#G#%0# 3674&>#%-*.%-3%'#+%# JUY>#0"'#'.'74#86%# 9"*4&%(%-#%0#+%'"&&4004# +%0# 3674&.that’s where it’s at: metabolic changes in tumors. )*(+./-#+%# 0"# 94'9"3"'"# Rb<J># 0"# (6"0# "(3C"#(474#6-#&%.'34-"'#$4&#"(%)0"(.+"+#+%#UbR#(.*%0# +%#/&.'#+%#UbR#$4&#94'94&. Pedersen PL (2007)./-#$"&"#'45&%*.&%-#71'#gLW#86%# $&4*486%-#71'#763"(./-#4O.# 0"# (:060"# 3674&"0#$4'%%# &63"'# 7%3"5/0.(:"2!$=>#+%# U\3>#0"#R^fZ># G# 43&"# '.)%-+4# 6-#&%(.'#!"#$%@#AIIaB>#(474#"#-. Annual Review Pathology 5: 253-295."# +%#0"# . Journal Bioenergetics Biomembranes 39: 211-222.("'>#86%# -4#%'31-#$&%'%-3%'#%-#0"'#(:060"'#-4&7"0%'.-"'"# 86%#9"*4&%(%#0"#'6$%&*."(.&%(3">#"#3&"*:'#+%#0"#$&4+6((./-#%-3&%# Rb<J#G#b^dUg>#+%#94&7"# 86%# 0"#+%'&%.>AII]B.'74#3674&"0#3"75.:)(4#=b.'#G# W. Sugar and fat .7%-3"(. Warbug O.60"(.("'#C-. Hanahan D.#AII@B. Negelein E (1924).'74#+%0#(1-(%&>#'. Harris AL. Warbug. Bibliografía citada: • • • • • • • • • • • • • • • • Gottlieb E.7"'#(0"*%'#%-#0"# &%. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis."-+4#:'3%# 0"(3"34#2"(P"#%0#2P./-#'%# %O)%-+%#2"'3"# %0# -.(04#+%# c4&.&"-#("-)+"+#+%#$&4+6(34'#3/O.# <'3"#"(%)D 0"(.'+"0%#AIIAB./-#+%#b^dUg#(47$&47%3%#0"#%O$&%'.#+%# 0"# Uc!# #. Trachooman D.7$0. Über den Stoffweschsel der tumoren.34(4-+&. Weinberg RA (2011).# <'3"# &%0"(.-(0".#<'3"'#G#43&"'#$&%.-"#+%# 0"'#2.'74'#+%# +%34O.*(+.*%0#%$."-4'># +%# 94&7"# 86%#'%# %'3"50%(%# 6-"#%'$%(. Mammalian sirtuins: biological insights and disease relevance.+")*"#=Z46\46D &"\. Mazurek S. Boschek CB. Giatromanolaki A.*"''.%-%&"#+%# 0"#%0%*"+"#"()*.+"+#7%3"5/0.46#!"#$%.'. ATP citrate lyase inhibition can suppress tumor cell growth. Huang P (2009)."+"#$4&#gJU./-#7%+.7"&. me and Hexokinase 2: Multiple discoveries of key molecular events underliying one of cancer´s most common phenotypes the “Warbug effect”.N"-+4#%'3"'#C0)7"'#%0#0"(3"34#$"&"# &%."-4'># %-#0"# 7%+. Andreadis C.5 ¦ Nº 138-139 ."#+%#'6#"()*.#"+-/7/*$'0*6:('2+ F"'3"# "24&"# '%# 2"# 2%(24#%*.D -"-+4#"86%004'#86%#-4#'4-#-6(0%/'. Zhao F.6&># AIIXB..'7"'. Cell 144: 646-674 Hatzivassiliou G. Hugo F.4'#%-#+%3%&7."'#"#0"# "((. Hallmarks of cancer: the next generation. Nature Reviews Cancer 7: 763-777.(04#+%#&%3&4"0. Pyruvate Kinase type M2 and its role in tumor growth and spreading.-+.3"+">#0"'#(:060"'#3674&"0%'#. Altomare DA.#S1'#%'96%&N4#'%#+%5%#$4-%&#%-# +. Nature 358: 6-15. Mitochondrial tumor supressors: a genetic and biochemical update. Sivridis E (2006). Kuhajda FP.%-3%#+%#*403"T%#=`YUcB#=R%+%&'%->#AIIeBK#%'3"#"'4(./-#+%# Rb<J#%'#00%*"+"#"#("54#96-+"7%-3"07%-3%# $4&#gLW.%-'2#& !4' #3674&%'#'%# (47$4&3"-# (474#/&.#W%#$6%+%#%'3"50%(%&#"86P#6-"#(4-%O."'"#=Uc!B./-#$6%+%# &%*%&)&'%# .# '4-#-%(%'"&./-# +%0# 7%3"540.(. Nature Reviews Cancer 2 862-871.*.60"(.4-%'>#%-3&"-+4#%-#6-#(. Nature reviews cancer 5: 857-866. Menendez JA.36"+"# <.